Back to Search Start Over

Genetic risk factors for COVID-19 and influenza are largely distinct.

Authors :
Kosmicki JA
Marcketta A
Sharma D
Di Gioia SA
Batista S
Yang XM
Tzoneva G
Martinez H
Sidore C
Kessler MD
Horowitz JE
Roberts GHL
Justice AE
Banerjee N
Coignet MV
Leader JB
Park DS
Lanche R
Maxwell E
Knight SC
Bai X
Guturu H
Baltzell A
Girshick AR
McCurdy SR
Partha R
Mansfield AJ
Turissini DA
Zhang M
Mbatchou J
Watanabe K
Verma A
Sirugo G
Ritchie MD
Salerno WJ
Shuldiner AR
Rader DJ
Mirshahi T
Marchini J
Overton JD
Carey DJ
Habegger L
Reid JG
Economides A
Kyratsous C
Karalis K
Baum A
Cantor MN
Rand KA
Hong EL
Ball CA
Siminovitch K
Baras A
Abecasis GR
Ferreira MAR
Source :
Nature genetics [Nat Genet] 2024 Aug; Vol. 56 (8), pp. 1592-1596. Date of Electronic Publication: 2024 Aug 05.
Publication Year :
2024

Abstract

Coronavirus disease 2019 (COVID-19) and influenza are respiratory illnesses caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses, respectively. Both diseases share symptoms and clinical risk factors <superscript>1</superscript> , but the extent to which these conditions have a common genetic etiology is unknown. This is partly because host genetic risk factors are well characterized for COVID-19 but not for influenza, with the largest published genome-wide association studies for these conditions including >2 million individuals <superscript>2</superscript> and about 1,000 individuals <superscript>3-6</superscript> , respectively. Shared genetic risk factors could point to targets to prevent or treat both infections. Through a genetic study of 18,334 cases with a positive test for influenza and 276,295 controls, we show that published COVID-19 risk variants are not associated with influenza. Furthermore, we discovered and replicated an association between influenza infection and noncoding variants in B3GALT5 and ST6GAL1, neither of which was associated with COVID-19. In vitro small interfering RNA knockdown of ST6GAL1-an enzyme that adds sialic acid to the cell surface, which is used for viral entry-reduced influenza infectivity by 57%. These results mirror the observation that variants that downregulate ACE2, the SARS-CoV-2 receptor, protect against COVID-19 (ref. <superscript>7</superscript> ). Collectively, these findings highlight downregulation of key cell surface receptors used for viral entry as treatment opportunities to prevent COVID-19 and influenza.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
1546-1718
Volume :
56
Issue :
8
Database :
MEDLINE
Journal :
Nature genetics
Publication Type :
Academic Journal
Accession number :
39103650
Full Text :
https://doi.org/10.1038/s41588-024-01844-1